CN1136880C - Combined Chinese and Western medicine for treating bronchial asthma - Google Patents
Combined Chinese and Western medicine for treating bronchial asthma Download PDFInfo
- Publication number
- CN1136880C CN1136880C CNB011040351A CN01104035A CN1136880C CN 1136880 C CN1136880 C CN 1136880C CN B011040351 A CNB011040351 A CN B011040351A CN 01104035 A CN01104035 A CN 01104035A CN 1136880 C CN1136880 C CN 1136880C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- radix
- bronchial asthma
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 208000006673 asthma Diseases 0.000 title claims abstract description 30
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title claims abstract description 19
- 238000002347 injection Methods 0.000 claims abstract description 22
- 239000007924 injection Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 210000002826 placenta Anatomy 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims description 71
- 235000013351 cheese Nutrition 0.000 claims description 11
- 241000208340 Araliaceae Species 0.000 claims description 10
- 241000237636 Pheretima Species 0.000 claims description 10
- 241000522620 Scorpio Species 0.000 claims description 10
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 9
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000009490 scorpio Substances 0.000 claims description 8
- 238000007796 conventional method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 241000628997 Flos Species 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 4
- 229940126673 western medicines Drugs 0.000 abstract 2
- 241000218671 Ephedra Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 241000161991 Fargesia Species 0.000 abstract 1
- 241001662275 Gekko gigante Species 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 239000011505 plaster Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 10
- 230000008859 change Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 208000037656 Respiratory Sounds Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 201000006306 Cor pulmonale Diseases 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 4
- 206010047924 Wheezing Diseases 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000002048 spasmolytic effect Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 3
- 229960003556 aminophylline Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000037 inhalation toxicity test Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010007522 Cardiac asthma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000004327 Paroxysmal Dyspnea Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010059411 Prolonged expiration Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a medicine for treating bronchial asthma by combining traditional Chinese medicines and western medicine, which is composed of traditional Chinese medicines and western medicines, wherein the traditional Chinese medicines comprise dried giant gecko, plaster, human placenta, raw membranous milkvetch root, pinellia tuber, earthworm, liquoric root, epimedium herb, ephedra, apricot kernel, white fargesia, rhizoma drynariae, ledebouriella root, schisandra fruit, ginseng, ophiopogon root, common yan rhizome and scorpion as raw materials, all of which are made into orally taken traditional Chinese medicines and then combine western medicines of acupoint injection therapies to treat bronchial asthma. The medicine for treating bronchial asthma has the advantages and effects of high cure rate, short course of disease, low relapse rate and no toxic or side effect.
Description
The present invention relates to the medicine of a cover treatment bronchial asthma, specifically it is to be the medicament of the Western medicine therapeutic alliance bronchial asthma of the Chinese medicine made according to a conventional method of raw material and acupoint injection therapy with the Chinese herbal medicine.
Bronchial asthma abbreviates asthma as, it is a kind of nonspecific inflammation disease of respiratory tract, its clinical characters is ictal uncomfortable in chest, cough, the expiratory dyspnea that is wheezing sound, the prevalence of China's asthma is 0.5-2%, the area that has is up to 5%, and age of onset is lighter, in life bringing inconvenience, even caused serious burden for society and family, aspect treatment, first elect the hormone inhalation both at home and abroad at present, effective, side effect is little, but need often take, easily outbreak after the drug withdrawal, the conventional treatments of doctor trained in Western medicine is a spasmolytic, antiinflammatory, eliminate the phlegm, the cough-relieving four processes, but effect also makes the patient not satisfied, and side effect is many, and untoward reaction is common, the aminophylline that medication is general, dexamethasone, be the spasmolytic antiallergic, select the antiinflammatory medicine simultaneously for use.The aminophylline untoward reaction is more obvious, and the patient is relatively painful, some patient even be difficult to stand, dexamethasone is the hormone drug class, and often application easily causes multiple side effect, also brings many future troubles to the patient, the unsuitable prolonged application in antibiotic medicine easily develops immunity to drugs, constipation, dysbacteriosis and relapse rate height.
Purpose of the present invention is the shortcoming and deficiency in order to overcome above-mentioned prior art just, and provide a kind of is the medicine of a cover treatment bronchial asthma of the Chinese medicine made of raw material and Western medicine acupoint injection therapy with the Chinese herbal medicine, thereby can effectively treat this kind disease, the patient is got well early.
The objective of the invention is to realize by following technical proposal:
The medicine of one cover treatment bronchial asthma is made up of Chinese medicine and Western medicine, and it is to carry out decocting according to a conventional method with following materials of weight proportions to it is characterized in that described Chinese medicine, extracts the capsule that medicinal liquid is made through concentrated, dry powder process:
Dried Gecko 20-40 part Gypsum Fibrosum 5-15 part Placenta Hominis 5-15 part Radix Astragali 10-30 part
Rhizoma Pinelliae 5-10 part Pheretima 5-15 part Radix Glycyrrhizae 5-15 part Herba Epimedii 5-15 part
Herba Ephedrae 5-15 part Semen Armeniacae Amarum 5-15 part Rhizoma Atractylodis Macrocephalae 10-30 part Rhizoma Drynariae 5-15 part
Radix Saposhnikoviae 5-15 part Fructus Schisandrae Chinensis 5-15 part Radix Ginseng 5-15 part 10-20 Radix Ophiopogonis part
Rhizoma Dioscoreae 10-30 part Scorpio 5-15 part.
Described Western medicine is nuclear cheese and Si Qikang injection.
The preferred weight proportioning of each raw material of Chinese medicine of the present invention is:
Dried Gecko 25-35 part Gypsum Fibrosum 10-15 part Placenta Hominis 8-10 part Radix Astragali 15-25 part
Rhizoma Pinelliae 8-10 part Pheretima 8-10 part Radix Glycyrrhizae 8-10 part Herba Epimedii 8-10 part
Herba Ephedrae 10-15 part Semen Armeniacae Amarum 8-10 part Rhizoma Atractylodis Macrocephalae 15-20 part Rhizoma Drynariae 8-12 part
Radix Saposhnikoviae 8-12 part Fructus Schisandrae Chinensis 8-12 part Radix Ginseng 15-20 part 812 parts of Radix Ophiopogonis
Rhizoma Dioscoreae 15-20 part Scorpio 8-12 part.
The optimum weight proportioning of each raw material of Chinese medicine of the present invention is:
20 parts of 10 parts of Radix Astragali of 10 parts of Placenta Hominiss of 30 parts of Gypsum Fibrosum of dried Gecko
10 parts of 10 parts of Herba Epimedii of 10 portions of Radix Glycyrrhizaes of 10 parts of Pheretimas of the Rhizoma Pinelliae
10 parts of 20 parts of Rhizoma Drynariae of 10 parts of Rhizoma Atractylodis Macrocephalaes of 10 parts of Semen Armeniacae Amarums of Herba Ephedrae
15 parts of 10 parts of Radix Ginsengs of 10 parts of Fructus Schisandrae Chinensis of Radix Saposhnikoviae 10 parts of Radix Ophiopogonis
10 parts of 20 portions of Scorpios of Rhizoma Dioscoreae.
As patient the time, can also in each raw material of Chinese medicine, add and also can add Herba Houttuyniae 20-40 part, Flos Lonicerae 10-30 part, Fructus Forsythiae 5-15 part, Cortex Mori 5-15 part with inflammation.
When acute attack, increase Dingchuan, SHANZHONG acupoint Triamcinolone Acetonide injection injection.
The patient of bronchial asthma, suppress outbreak anoxia repeatedly because of breathing heavily, the lung repeated infection, continuous contact allergy source, the adrenal cortex secretion is very not enough in of a specified duration causing, and the normal person secretes hydrocortisone 25mg every day, secrete 250mg in case of necessity, when functional disorder, acth secretion reduces, and general weakness can occur, the waist lower limb is soft, the resisting cold ability is very low.Modern medicine study thinks that bronchial asthma has the evidence of hypophysis-hypoadrenocorticism, confirm through literature survey research and pharmacological research, kidney-reinforcing drug can improve this function, illustrate that the kidney invigorating therapy meets modern medical theory, through for many years clinical practice proof its by increasing effect of adrenal cortex function, promote the body cell metabolism, improve the low situation of body's immunity, improve the nonspecific defense function of body, can resist the change and the extraneous infective agent of weather, pathological change is developed towards the direction that helps the body reparation, pass through acupoint injection therapy again, stimulating acupoint is brought about the desired sensation, dredging the meridian, QI and blood, negative and positive are regulated internal organs, therapy of combining Chinese and Western medicine, specimen is held concurrently solid, and the performance cooperative effect promotes early recovery.
Chinese medicine preparation of the present invention is according to theory of Chinese medical science, sums up in conjunction with clinical practice for many years, and wherein raw material Gecko, Radix Astragali, Pheretima, Herba Ephedrae Scorpio are monarch drug, Gypsum Fibrosum, Fructus Schisandrae Chinensis, Radix Ginseng, Radix Ophiopogonis are ministerial drug, and all the other are adjuvant, and its property of medicine is invigorating the kidney and spleen, double solid cardiopulmonary, eliminating phlegm and stopping cough, lung qi dispersing helps the kidney improving inspiration by invigorating kidney-QI, can control the body deficient syndrome, can prevent acute attack again, promptly specimen is held concurrently admittedly, prevents and treats combination again.
Acupoint injection therapy, conventional acupoint selection are Dingchuan, Danzhong, canopy, Tiantu.
Acupuncture point effect: DINGCHUAN acupoint: can relieving asthma and cough, lung qi dispersing is regulated the flow of vital energy; Point cv 20: can resolving phlegm and relieving asthma, the sending down the abnormal ascending QI cough-relieving, SHANZHONG acupoint: can the lung qi dispersing the chest stuffiness relieving, the mind calming pain relieving; TIANTU acupoint is that acupoints on Ren channel potential energy lung qi dispersing is had one's ideas straightened out sore-throat relieving eliminating stagnation, eliminating phlegm and lowering adverse QI.All caves cooperate injection to play the effect of lowering the adverse-rising QI to subdue asthma expectorant altogether.
The Western medicine Triamcinolone Acetonide is a hormone medicine, is used for acute attack, has antiinflammatory, anti-allergic effects, effectively controlling symptoms.Si Qikang and nuclear cheese can improve the immunity of body, prevent flu, and the two share also is that specimen is held concurrently admittedly.
Clinical drug result of the present invention:
1, materials and methods:
The 1-1 object of study:
Whole case 800 examples are according to medical history, symptom and lab testing are diagnosed as mixed type bronchial asthma, persistent state to asthma gives antiinflammatory, antibiotic, the state of an illness tides over a critical period after the oxygen uptake anti symptom treatment, divides treatment group and matched group by the random packet principle, and 200 examples are organized in treatment, man's 105 examples, women 95 examples, the oldest 70 years old, minimum 5 years old, 40 years old mean age, the course of disease was the longest 50 years, the shortest 2 years, merge coronary heart disease 42 examples, chronic emphysema 62 examples, pulmonary heart disease 20 examples, pulmonary infection 53 examples, contrast I organizes 200 examples, male 97 examples, woman's 103 examples, older 72 years old, minimum 1.5 years old, 38.7 years old mean age, the course of disease is the longest 48 years, the shortest 1 year, merge coronary disease 42 examples, chronic emphysema 62 examples, pulmonary heart disease 20 examples, pulmonary infection 57 examples; Contrast II organizes 200 examples, male 100 examples, and women 100 examples, the oldest 71 years old, minimum 2.5 years old, 39 years old mean age, the course of disease is the longest 51 years, and was the shortest 1.5 years, merged coronary heart disease 45 examples, chronic emphysema 65 examples, pulmonary heart disease 23 examples, pulmonary infection 47 examples.Contrast III organizes 200 examples, male 101 examples, and women 99 examples, the oldest 73 years old, minimum 3 years old, 40.5 years old mean age, the course of disease was the longest 55 years, and the shortest person 2 years merges coronary heart disease 45 examples, chronic emphysema 63 examples, pulmonary heart disease 21 examples, pulmonary infection 37 examples.
The 1-2 diagnosis basis:
1) symptoms of asthma is shown effect repeatedly, is expiratory dyspnea during outbreak;
2) family history and individual allergies are often arranged;
3) cough, cough up phlegm, breast is vexed;
4) with after the bronchiectasis medicine treatment, block situation and alleviate fully or in various degree;
5) following test can cause outbreak:
The acetylcholine inhalation test, histamine's inhalation test, exercise stress test;
6) Signs: thorax is full, be air-breathing shape, the lung increased response, the turbid boundary of liver descends, border of cardiac dullness dwindles, two lung audibles are inhaled high-pitched tone wheezing sound widely, and expiratory duration prolongs, when pulmonary infection is arranged, audible and moist rale, serious asthma attack can have the auxiliary activity of respiratory muscle, the serious asthma person's dyspnea aggravation of paradoxical pulse part, and wheezing sound alleviates middle disappearance on the contrary;
7) lab testing: eosinophilia in the blood, LgE increases;
8) increased bronchovascular shadows in the rabat, transparency increases, and heart is the shape of dangling;
9) asthma that other pathological changes causes except, as cardiac asthma, chronic asthmatic tracheitis, mediastinal tumor, spontaneous pneumothorax.
The 1-3 Therapeutic Method:
Treatment group and matched group 28 days were a course of treatment, contrasted after treating three courses of treatment, and medicine of the present invention for oral use is organized in treatment, every day three times, each 8, every 0.5g.
Acupoint injection therapy: Si Qikang, nuclear cheese, each 2ml.
Acupuncture point: Dingchuan, Danzhong, Tiantu, canopy.
Acupoint injection therapy on the three once exchanged Si Qikang, nuclear cheese every three days.
Increase Dingchuan, SHANZHONG acupoint are injected with the scorching relaxed and comfortable A that dispels when acute attack, and three once, each 2ml.
Contrast I group: oral middle medicament of the present invention, consumption serve on three courses of treatment with the treatment group.
Contrast II group: acupoint injection therapy, with treatment group consumption and method.
Contrast III group: conventional Western medicine aminophylline 0.25g adds 5% glucose 500ml, cefradine number added quiet of 0.9% sodium chloride 250ml 7-10 days, oral again cefalexin, a 0.5g, four times on the one, take spasmolytic such as ammonia tea sign indicating number alkali, powerful expectorant spirit, Radix Glycyrrhizae tabellae simultaneously, the scorching drug dosage of dispelling is by generally oral in the explanation, removes antibiotics a course of treatment, continue with other reduce phlegm, the spasmolytic medicine.
2 therapeutic outcomes: use X 2 test, ask the P value, following seven point plan contrast:
2-1, treatment are after seven days, and prolonged expiration is accompanied the variation of high-pitched tone wheezing sound in the auscultation:
See Table 1:
Compare with contrast III group: X
2There is higher significant difference=53.75 P＜0.01.
Table 1
Group sign disappear to reduce no change and add up to
Example (%) example (%) example (%)
Treatment group: 150 (75) 42 (21) 8 (4) 200
Contrast I group: 125 (62.5) 39 (19.5) 36 (18) 200
Contrast II group: 107 (53.5) 37 (18.5) 56 (28) 200
Contrast III group: 101 (50.5) 35 (17.5) 64 (32) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=20.22 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=43.52 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=53.75 P＜0.01.
The change of 2-2, treatment amount of expectoration after seven days: is patient's the amount of spitting 1 minute by every 5ml, and with the change situation of integration method mensuration amount of expectoration, 0 is divided into recovery from illness, and 1-10 is divided into improvement, little for changing more than 11 minutes, sees Table 2.
Table 2
Group 0 fen 1-10 of sign divide more than 11 minutes and add up to
Example (%) example (%) example (%)
Treatment group: 130 (65) 60 (30) 10 (5) 200
Contrast I group: 89 (44.5) 37 (18.5) 74 (37) 200
Contrast II group: 101 (50.5) 35 (17.5) 64 (32) 200
Contrast III group: 87 (43.5) 35 (17.5) 78 (39) 200
Contrast II group: 101 (50.5) 35 (17.5) 64 (32) 200
Contrast III group: 87 (43.5) 35 (17.5) 78 (39) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=61.87 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=49.60 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=67.60 P＜0.01.
Eosinophilic granulocyte's change sees Table 3 in 2-3, a treatment bleeding from anus course of treatment
Table 3
Group normal (≤5%) higher (〉=6%) of chemical examination add up to
Example (%) example (%)
Treatment group: 182 (91) 18 (9) 200
Contrast I group: 131 (65.5) 69 (34.5) 200
Contrast II group: 140 (50.5) 60 (30) 200
Contrast III group: 127 (43.5) 73 (36.5) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=38.19 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=26.83 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=43.02 P＜0.01.
The change of IgE sees Table 4 in 2-4, a treatment bleeding from anus course of treatment
Table 4
Group chemical examination normal (≤0.9mg/100hp serum) higher (〉=1.0mg/100hp serum adds up to
Example (%) example (%)
Treatment group: 192 (96) 8 (4) 200
Contrast I group: 147 (73.5) 53 (26.5) 200
Contrast II group: 135 (67.5) 65 (32.5) 200
Contrast III group: 13 (68.5) 63 (31.5) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=39.17 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=54.42 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=51.79 P＜0.01.
The change of 2-5, treatment vital capacity three courses of treatment: see Table 5
Normal vital capacity is 2400-4000ml
On the low side is 10001ml≤vital capacity≤24001ml
Difference is 300≤vital capacity＜1000ml
Table 5
Group the normally low difference of vital capacity add up to
Example (%) example (%) example (%)
Treatment group: 155 (75.5) 37 (18.5) 8 (4) 200
Contrast I group: 110 (55) 37 (19.5) 53 (26.5) 200
Contrast II group: 115 (57.5) 34 (17) 51 (25.5) 200
Contrast III group: 103 (51.5) 29 (14.5) 68 (34) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=40.83 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=37.36 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=58.8 P＜0.01.
The change of 2-6 treatment lung marking and transparency after three months sees Table 6:
In our treatment, to comparing with the rabat for the treatment of three courses of treatment before the patient treatment, improvement along with patient's lung marking and transparency, the heart external form is also changed into normal morphology by original suspended pattern, in the table rabat lung lung marking and transparency improvement situation is divided into normally, alleviates, three kinds of no changes.
Table 6:
Group rabat normally alleviate invalid total
Example (%) example (%) example (%)
Treatment group: 172 (86) 20 (10) 8 (4) 200
Contrast I group: 110 (55) 30 (15) 60 (30) 200
Contrast II group: 106 (53) 30 (17) 64 (32) 200
Contrast III group: 100 (51.5) 29 (14.5) 71 (35.5) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=55.36 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=61.22 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=70.92 P＜0.01.
2-7 with remembering 3 years, recurs the comparison of situation: see Table 7 to whole patients
Group morbidity send out back mild symptoms recurrence and add up to
Example (%) example (%) example (%)
Treatment group: 164 (82) 26 (13) 10 (5) 200
Contrast I group: 93 (46.5) 20 (10) 87 (43.5) 200
Contrast II group: 85 (42.5) 17 (8.5) 98 (49) 200
Contrast III group: 37 (18.5) 12 (6) 151 (75.5) 200
The treatment group compares with contrast I group: X
2There is higher significant difference=82.84 P＜0.01.
The treatment group compares with contrast II group: X
2There is higher significant difference=102.38 P＜0.01.
The treatment group compares with contrast III group: X
2There is higher significant difference=206.79 P＜0.01.
Relatively taking Chinese Medicine and Clavicular acupoint injection therapy of the present invention treatment bronchial asthma by above seven aspects more all has higher significant difference with other three kinds of Therapeutic Method, has confirmed that medicine of the present invention is meaningful to treating bronchitis in clinical practice.
The present invention compares following advantage of tool and effect with technology:
A) medicine of the present invention is the invigorating the kidney and spleen with Chinese medicine, double solid cardiopulmonary, the deficient syndrome of can effecting a permanent cure can prevent acute attack again, accomplish that promptly specimen is double solid, the control combination by acupoint injection therapy dredging the meridian, QI and blood, negative and positive, is regulated internal organs, the Chinese and western medicine synergism, promote the early recovery of disease, greatly improve the immunity of body, prevent recurrence.
B) patient paid a return visit in 3 years, did not find toxic and side effects, and relapse rate 46%;
C) combination science, rationally, preparation method is simple;
D) consumption is few, instant effect, and cure rate 91.3%, effective percentage reaches more than 98%.
Embodiment 1:
Get dried Gecko 30g, Gypsum Fibrosum 10g, Placenta Hominis 10g, Radix Astragali 20g, Rhizoma Pinelliae 10g, Pheretima 10g, Radix Glycyrrhizae 10g, Herba Epimedii 10g, Herba Ephedrae 10g, Semen Armeniacae Amarum 10g, Rhizoma Atractylodis Macrocephalae 20g, Rhizoma Drynariae 10g, Radix Saposhnikoviae 10g, Fructus Schisandrae Chinensis 10g, Radix Ginseng 10g, Radix Ophiopogonis 15g, Rhizoma Dioscoreae 20g, Scorpio 10g carries out decocting according to a conventional method after the mixing, extract medicinal liquid and make capsule through concentrated, dry powder process, every 0.5g, packing inspection is qualified to be product.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide.
Embodiment 2:
Get dried Gecko 20g, Gypsum Fibrosum 5g, Placenta Hominis 15g, Radix Astragali 30g, Rhizoma Pinelliae 5g, Pheretima 15g, Radix Glycyrrhizae 5g, Herba Epimedii 5g, Herba Ephedrae 15g, Semen Armeniacae Amarum 5g, Rhizoma Atractylodis Macrocephalae 30g, Rhizoma Drynariae 5g, Radix Saposhnikoviae 15g, Fructus Schisandrae Chinensis 5g, Radix Ginseng 15g, Radix Ophiopogonis 10g, Rhizoma Dioscoreae 30g, Scorpio 5g carries out decocting according to a conventional method after the mixing, extract medicinal liquid and make capsule through concentrated, dry powder process, every 0.5g, packing inspection is qualified to be product.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide
Embodiment 3:
Get dried Gecko 50g, Gypsum Fibrosum 15g, Placenta Hominis 5g, Radix Astragali 10g, Rhizoma Pinelliae 10g, Pheretima 5g, Radix Glycyrrhizae 15g, Herba Epimedii 15g, Herba Ephedrae 5g, Semen Armeniacae Amarum 15g, Rhizoma Atractylodis Macrocephalae 10g, Rhizoma Drynariae 15g, Radix Saposhnikoviae 5g, Fructus Schisandrae Chinensis 15g, Radix Ginseng 5g, Radix Ophiopogonis 20g, Rhizoma Dioscoreae 10g, Scorpio 15g carries out decocting according to a conventional method after the mixing, extract medicinal liquid and make capsule through concentrated, dry powder process, every 0.5g, packing inspection is qualified to be product.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide.
Embodiment 4:
Add Herba Houttuyniae 20g in the raw material in embodiment 1 again, Flos Lonicerae 25g, Fructus Forsythiae 10g, Cortex Mori 10g makes capsule more as stated above.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide.
Embodiment 5:
Add Herba Houttuyniae 30g in the raw material in embodiment 2 again, Flos Lonicerae 30g, Fructus Forsythiae 5g, Cortex Mori 15g makes capsule more as stated above.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide.
Embodiment 6:
Add Herba Houttuyniae 40g in the raw material in embodiment 3 again, Flos Lonicerae 10g, Fructus Forsythiae 15g, Cortex Mori 5g makes capsule more as stated above.
Acupoint injection therapy nuclear cheese and Si Qikang during treatment, acute attack increases Triamcinolone Acetonide.
Claims (5)
1, the medicine of a cover treatment bronchial asthma is made up of Chinese medicine and Western medicine, and it is to carry out decocting according to a conventional method with following materials of weight proportions to it is characterized in that described Chinese medicine, extracts the capsule that medicinal liquid is made through concentrated, dry powder process:
Dried Gecko 20-40 part Gypsum Fibrosum 5-15 part Placenta Hominis 5-15 part Radix Astragali 10-30 part
Rhizoma Pinelliae 5-10 part Pheretima 5-15 part Radix Glycyrrhizae 5-15 part Herba Epimedii 5-15 part
Herba Ephedrae 5-15 part Semen Armeniacae Amarum 5-15 part Rhizoma Atractylodis Macrocephalae 10-30 part Rhizoma Drynariae 5-15 part
Radix Saposhnikoviae 5-15 part Fructus Schisandrae Chinensis 5-15 part Radix Ginseng 5-15 part 10-20 Radix Ophiopogonis part
Rhizoma Dioscoreae 10-30 part Scorpio 5-15 part,
Described Western medicine is nuclear cheese and Si Qikang injection.
2, the medicine of a cover treatment bronchial asthma according to claim 1, it is characterized in that described Chinese medicine wherein the weight proportion of each raw material be:
Dried Gecko 25-35 part Gypsum Fibrosum 10-15 part Placenta Hominis 8-10 part Radix Astragali 15-25 part
Rhizoma Pinelliae 8-10 part Pheretima 8-10 part Radix Glycyrrhizae 8-10 part Herba Epimedii 8-10 part
Herba Ephedrae 10-15 part Semen Armeniacae Amarum 8-10 part Rhizoma Atractylodis Macrocephalae 15-20 part Rhizoma Drynariae 8-12 part
Radix Saposhnikoviae 8-12 part Fructus Schisandrae Chinensis 8-12 part Radix Ginseng 8-12 part 15-20 Radix Ophiopogonis part
Rhizoma Dioscoreae 15-20 part Scorpio 8-12 part.
3, the medicine of a cover treatment bronchial asthma according to claim 1, it is characterized in that described Chinese medicine wherein the weight proportion of each raw material be:
20 parts of 10 parts of Radix Astragali of 10 parts of Placenta Hominiss of 30 parts of Gypsum Fibrosum of dried Gecko
10 parts of 10 parts of Herba Epimedii of 10 portions of Radix Glycyrrhizaes of 10 parts of Pheretimas of the Rhizoma Pinelliae
10 parts of 20 parts of Rhizoma Drynariae of 10 parts of Rhizoma Atractylodis Macrocephalaes of 10 parts of Semen Armeniacae Amarums of Herba Ephedrae
15 parts of 10 parts of Radix Ginsengs of 10 parts of Fructus Schisandrae Chinensis of Radix Saposhnikoviae 10 parts of Radix Ophiopogonis
10 parts of 20 portions of Scorpios of Rhizoma Dioscoreae.
4, a cover treatment bronchial asthma medicine according to claim 1 is characterized in that also can adding Herba Houttuyniae 20-40 part, Flos Lonicerae 10-30 part, Fructus Forsythiae 5-15 part, Cortex Mori 5-15 part in the raw material of Chinese medicine.
5, the medicine of a cover treatment bronchial asthma according to claim 1 is characterized in that described Western medicine also has the Triamcinolone Acetonide injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011040351A CN1136880C (en) | 2001-02-19 | 2001-02-19 | Combined Chinese and Western medicine for treating bronchial asthma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011040351A CN1136880C (en) | 2001-02-19 | 2001-02-19 | Combined Chinese and Western medicine for treating bronchial asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1310002A CN1310002A (en) | 2001-08-29 |
| CN1136880C true CN1136880C (en) | 2004-02-04 |
Family
ID=4653634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011040351A Expired - Lifetime CN1136880C (en) | 2001-02-19 | 2001-02-19 | Combined Chinese and Western medicine for treating bronchial asthma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1136880C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101711830B (en) * | 2009-12-14 | 2011-07-27 | 刘桂青 | Traditional Chinese medicine composition for treating chronic bronchitis |
| CN102441105A (en) * | 2011-12-02 | 2012-05-09 | 香河县气管炎哮喘医院 | Traditional Chinese medicine for treating trachitis and asthma |
| CN103505707B (en) * | 2013-09-22 | 2015-07-15 | 广东省中医院 | Traditional Chinese medicinal preparation for treating asthma and preparation method of traditional Chinese medicinal preparation |
| CN103721231A (en) * | 2013-12-30 | 2014-04-16 | 于义琴 | Asthma injection nursing medicine and preparation method thereof |
| CN105250755A (en) * | 2015-10-19 | 2016-01-20 | 王迁 | Medicine for treating bronchitis based on traditional Chinese and western medicine therapy and preparation method of medicine |
| CN106266536B (en) * | 2016-08-23 | 2017-10-31 | 香河县气管炎哮喘医院 | It is a kind of to treat Chinese medicinal capsule of tracheitis, asthma and preparation method thereof |
| CN109893645A (en) * | 2018-11-21 | 2019-06-18 | 杨启祥 | A kind of drug of combination of Chinese tradiational and Western medicine acupoint therapy tracheitis, asthma |
-
2001
- 2001-02-19 CN CNB011040351A patent/CN1136880C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1310002A (en) | 2001-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN1167454C (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN1319569C (en) | Chinese medicine preparation for treating osteoporosis and fracture and preparation process thereof | |
| CN1297291C (en) | Medicine for abstaining from drug addiction and its preparation | |
| CN1136880C (en) | Combined Chinese and Western medicine for treating bronchial asthma | |
| CN1266693A (en) | Chinese medicinal composition for treating asthma and preparing process thereof | |
| CN1872235A (en) | Muskiness acesodyne ointment of chasing wind, and preparation method | |
| CN1175885C (en) | Zibei Cough stopping granules and its preparation method | |
| CN1192788C (en) | Medicine for resisting allergic reaction and its preparation method | |
| CN1136878C (en) | Combined Chinese and Western medicine for treating cardiopulmonary disease in catabasis | |
| CN1593493A (en) | Therapy assisting agent and its preparation | |
| CN1136881C (en) | Combined Chinese and Western medicine for treating pulmonary emphysema | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN1157219C (en) | Medicine for treating cancer | |
| CN1872306A (en) | Preparation of Chinese traditional medicine for treating baby's cough, and preparation method | |
| CN102836347B (en) | Traditional Chinese medicine for treating tinnitus | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1136879C (en) | Combined Chinese and Western medicine for treating chronic bronchitis in catabasis | |
| CN1250278C (en) | Oral medicine for treating dementia and feeblemindedpess | |
| CN1628770A (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN1973878A (en) | Medicine for treating epigastric pain in children and preparation method thereof | |
| CN1051018C (en) | Health bag for stomach and kidney | |
| CN1166379C (en) | Medicine for treating kidney disease and method for preparing same | |
| CN1682896A (en) | Medicine for treating infantile inflammation of upper respiratory tract and its preparing method | |
| CN101028488A (en) | Chinese medicine for chronic pharyngitis, esophagus inflammation and esophagus cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040204 |